scholarly journals Neonatal outcomes after neuraminidase inhibitor use during pregnancy: a meta‐analysis of cohort studies

2021 ◽  
Author(s):  
Jiangshan Lian ◽  
Munire Adilijiang ◽  
Caihua Chang ◽  
Hai‐yin Jiang ◽  
Yongping Zhang
Keyword(s):  
Cohort Studies ◽  
Meta Analysis ◽  
Neuraminidase Inhibitor ◽  
Neonatal Outcomes

scholarly journals Neonatal outcomes after neuraminidase inhibitor use during pregnancy: a meta-analysis of cohort studies

2021 ◽  
Author(s):  
Jiangshan Lian ◽  
Munire Adilijiang ◽  
Caihua Chang ◽  
Hai-yin Jiang ◽  
Yongping Zhang
Keyword(s):  
Cohort Studies ◽  
Influenza Infection ◽  
Meta Analysis ◽  
Antiviral Treatment ◽  
Neuraminidase Inhibitor ◽  
Neonatal Outcomes ◽  
Cochrane Library ◽  
Increased Risk ◽  
Adverse Neonatal Outcomes ◽  
Antiviral Medications

AIM: Influenza infection poses a severe threat to pregnant mothers, and antiviral treatment is recommended. However, the safety of neuraminidase-inhibitor antiviral medications during pregnancy has not been well described. METHODS: A systematic review and meta-analysis were performed to evaluate the adverse neonatal outcomes associated with exposure to neuraminidase inhibitors during pregnancy. The PubMed, Embase, and Cochrane Library databases were searched to identify potential studies for inclusion. RESULTS: Nine cohort studies that estimated adverse neonatal outcomes associated with exposure to neuraminidase-inhibitor medication during pregnancy were included. Exposure to a neuraminidase inhibitor during pregnancy was not associated with an increased risk of congenital malformation (odds ratio [OR] 0.9, 95% confidence interval [CI] 0.72–1.12, P = 0.341), low Apgar score (OR 0.96, 95% CI 0.77–1.2, P = 0.733), or preterm birth (OR 0.99, 95% CI 0.89–1.09, P = 0.771) compared with no exposure. However, exposure to a neuraminidase inhibitor was associated with a reduced risk of low birth weight (OR 0.79, 95% CI 0.68–0.92, P = 0.002) and giving birth to a small-for-gestational-age infant (OR 0.78, 95% CI 0.69–0.88, P < 0.001). Further analyses limited to oseltamivir exposure were consistent with the overall results. CONCLUSION: Exposure to neuraminidase-inhibitor medication during pregnancy does not appear to be associated with adverse neonatal outcomes. We recommend further studies to investigate this association, which will help clinicians determine whether to prescribe a neuraminidase inhibitor during pregnancy.

Effect of Alcohol Use Disorder and Alcohol Intake on Risk of Subsequent Depression: A Dose-Response Meta-Analysis of Cohort Studies

2019 ◽  
Author(s):  
Jingde Li ◽  
Hongxuan Wang ◽  
Mei Li ◽  
Qingyu Shen ◽  
Xiangpen Li ◽  
...  
Keyword(s):  
Alcohol Use ◽  
Cohort Studies ◽  
Dose Response ◽  
Alcohol Use Disorder ◽  
Alcohol Intake ◽  
Meta Analysis

Perioperative Mortality and Complications in Patients with COVID-19 Undergoing Surgery: A Meta-Regression and Meta-Analysis of 8 Cohort Studies

2020 ◽  
Author(s):  
Hai ping Ma ◽  
Hai Guo ◽  
Long Yang ◽  
Jian rong Ye ◽  
Chun ling Chen ◽  
...  
Keyword(s):  
Cohort Studies ◽  
Meta Analysis ◽  
Perioperative Mortality ◽  
Meta Regression

Dietary Fat Intake and Risk of Alzheimer’s Disease and Dementia: A Meta-Analysis of Cohort Studies

2018 ◽  
Vol 15 (9) ◽  
pp. 869-876 ◽  
Author(s):  
Yue Ruan ◽  
Jun Tang ◽  
Xiaofei Guo ◽  
Kelei Li ◽  
Duo Li
Keyword(s):  
Cohort Studies ◽  
Dietary Fat ◽  
Prospective Cohort ◽  
Meta Analysis ◽  
Saturated Fat ◽  
Fat Intake ◽  
Prospective Cohort Studies ◽  
Dietary Fat Intake ◽  
Dementia Risk ◽  
Saturated Fat Intake

Background: Epidemiological studies showed that dietary fat intake is associated with Alzheimer’s disease (AD) and dementia risk, however, the association remain inconsistent. This metaanalysis aimed to systematically examine the association of dietary fat intake with AD and dementia risk. Methods: We have systematically searched PubMed, Embase and the Cochrane Library up to May 1st 2017. Prospective cohort studies were included if they reported on the association of dietary fat intake with AD and dementia risk. Multivariate-adjusted relative risks (RRs) for the highest versus lowest category were pooled by using a random-effects model. Results: A total of 8630 participants and 633 cases from four independent prospective cohort studies were included in the present meta-analysis. A higher dietary saturated fat intake was significantly associated with an increased risk of 39% and 105% for AD (RR: 1.39; 95% CI: 1.00, 1.94) and dementia (RR: 2.05; 95% CI: 1.06, 3.98), respectively. Dose-response analysis indicated a 4 g/day increment of saturated fat intake was related to 15% higher risk of AD (RR: 1.15; 95% CI: 1.01, 1.31). However, there was no significant association found between dietary intake of total, monounsaturated, polyunsaturated fat and AD or dementia risk. Conclusions: This meta-analysis provides significant evidence of positive association between higher saturated fat intake and AD and dementia risk.

Sign in / Sign up

Export Citation Format

Share Document